DATE: March 27, 2018
TIME: 09:00am PDT, 12:00pm EDT

Advances in mass spectrometry instrumentation and sample handling methods have propelled proteomics and extended its utility for both basic biology and early drug development. Changes in protein abundance and post-translational modification state often reflect the activity of a novel therapeutic agent as well as the sensitivity/resistance of a biological system to treatment. For post-translational modifications, methods to enrich modified peptides from complex mixtures have played an important role. Chief among these is immunoaffinity enrichment, where antibodies directed against post-translational modifications (or remnants thereof) are used to capture analytes of interest for mass spectrometry analysis. To expand upon these methods, here we report on an automated PTMScan® immunoaffinity enrichment protocol, developed using the Phynexus MEA benchtop robot, for concurrent processing of up to twelve samples. System optimization has included interrogating the effects of peptide incubation, washing, and antibody-resin crosslinking on the sensitivity and specificity of this automated method. Using this technology in conjunction with Ubiquitin Remnant Motif (K-ε-GG), it is now possible to identify and quantify many >10,000 distinct ubiquitination events from cultured cells and tissue samples. This webinar will focus on the utility of the PTMScan method in early drug discovery and the future of automation in multiplexed analysis of cellular signaling.

During this webinar, viewers will learn about:

• How changes in post-translational modification can be used to assess activation states of novel therapeutic targets;
• Benchtop robot automation of the PTMScan® immunoaffinity enrichment protocol, enabling concurrent processing of 12 samples;
• Utility of the PTMScan® method for early drug discovery, and the future of automation in multiplexed analysis of cellular signaling.

PTMScan® is a registered trademark of Cell Signaling Technology, Inc.